ArticleJournal of orthopaedic surgery and research2025
miR-629-3p affects postmenopausal osteoporosis through targeted regulation of BACH1.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis (OP) represents a major global health challenge, particularly among postmenopausal women. Currently, there remains a shortage of reliable diagnostic biomarkers and targeted therapies for OP.
methodsA cohort of 254 postmenopausal women (127 OP patients and 127 healthy controls) was analyzed. Serum miR-629-3p levels were measured via qRT-PCR, and diagnostic potential was assessed using ROC analysis. In vitro, MC3T3-E1 osteoblasts were transfected with miR-629-3p mimic/inhibitor and BACH1 overexpression vector (oe-BACH1). Proliferation and apoptosis were evaluated by functional assays (CCK-8, Annexin V-FITC/PI staining), while osteogenic markers (FN1, ITGB1 and RUNX2) were assessed by qPCR. The binding of miR-629-3p to the BACH1 3'UTR was confirmed by luciferase reporter assays.
resultsOur findings revealed significantly decreased miR-629-3p levels in OP patients (P < 0.001), negatively correlating with BACH1 (r = -0.696, P < 0.001) and showing diagnostic potential (AUC = 0.929). Mechanistically, miR-629-3p mimic suppressed BACH1 (P < 0.001), enhancing proliferation, reducing apoptosis, and upregulating RUNX2 (all P < 0.001), while BACH1 overexpression reversed these effects. Luciferase assays confirmed miR-629-3p directly targets BACH1 3'UTR (P < 0.001).
conclusionmiR-629-3p attenuates OP progression by inhibiting BACH1, thereby promoting osteoblast survival, proliferation, and differentiation. Its diagnostic potential and therapeutic role in restoring osteogenic function highlight miR-629-3p/BACH1 as a promising axis for OP management. However, the findings of this study require further validation in animal models to fully establish causality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.